Not checked for notices yet.
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
Yumi Fujimoto, Tomoko Yamamori Morita, Akihiro Ohashi and 6 more
Scientific Reports · 2020
doi:10.1038/s41598-020-78646-y
Cited by papers we hold 3
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance · 2024No notice
- Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer · 2023No notice
- AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? · 2021No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.